Sanofi’s latest R&D remodeling spotlights what’s hot (bispecifics) and what’s not (CTLA-4) in oncology today
Sanofi’s pipeline remodeling program has claimed a pivotal combo approach to lung cancer along with a score of other terminations in Q4. And the moves underscore what’s hot — and not — in the oncology field.
Outlining the moves in their quarterly sit-down with analysts, Sanofi hit the kill switch on 13 development programs and 25 research projects. But the R&D group also hit the gas on 17 programs, about half of which are in oncology.
New R&D chief John Reed is pressing a strategy established by Elias Zerhouni, which involves more of an in-house focus, particularly in the wake of the recent Ablynx and Bioverativ buyouts, which added new research capabilities and drugs to the pipeline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.